Huang Tao
Department of Cardiothoracic Vascular Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities No. 18 Zhongshan Second Road, Baise 533000, Guangxi Zhuang Autonomous Region, People's Republic of China.
Am J Transl Res. 2022 Dec 15;14(12):8862-8878. eCollection 2022.
Cancer patients are reported to be more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the COVID-19 (the Corona Virus Disease 2019) patients with cancer suffer from certain serious complications. has been recently identified as a novel receptor of SARS-CoV-2 in human cells; however, there are limited studies on in various human cancers.
This study utilized a comprehensive analysis of COVID-19-related in multiple human cancers based on 18,589 multi-center samples. Using Wilcoxon rank-sum analysis, a difference in expression between cancer and control tissues was detected. Cox regression analysis, Kaplan-Meier curves, and receiver operating characteristic curves were utilized to determine the correlation between expression and the clinical parameters of cancer patients. The immune relevance and potential mechanisms of in various cancers were also investigated.
Abnormal mRNA expression was observed in 16 of 20 different cancers (e.g., it was upregulated in colon adenocarcinoma but downregulated in cholangiocarcinoma; < 0.05). was related to prognosis, e.g., overall survival, in 14 cancers ( < 0.05), such as adrenocortical carcinoma. The gene was also found to be a potential marker that can be utilized to distinguish eleven cancers from controls with moderate to high accuracy (e.g., the area under the curve for cholangiocarcinoma = 1.000). expression was related to DNA methyltransferases, mismatch repair genes, immune checkpoints, levels of tumor mutational burden, microsatellite instability, neoantigen count, and immune infiltration levels in certain cancers ( < 0.05). The gene plays a role in multiple cancers by affecting four signaling pathways, such as cytokine-cytokine receptor interaction. Cancer patients with high expression are sensitive to 25 drugs, including ulixertinib.
SARS-CoV-2-correlated is a novel marker that can be used for treating and identifying multiple human cancers.
据报道，癌症患者更容易感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2），而患有癌症的2019冠状病毒病（COVID-19）患者会出现某些严重并发症。最近已被确定为人类细胞中SARS-CoV-2的一种新型受体；然而，关于其在各种人类癌症中的研究有限。
本研究基于18589个多中心样本，对多种人类癌症中与COVID-19相关的进行了综合分析。使用Wilcoxon秩和分析检测癌症组织与对照组织之间表达的差异。采用Cox回归分析、Kaplan-Meier曲线和受试者工作特征曲线来确定表达与癌症患者临床参数之间的相关性。还研究了在各种癌症中的免疫相关性和潜在机制。
在20种不同癌症中的16种中观察到异常的mRNA表达（例如，在结肠腺癌中上调，但在胆管癌中下调；<0.05）。在14种癌症（<0.05）中，如肾上腺皮质癌，与预后相关，例如总生存期。该基因还被发现是一种潜在的标志物，可用于以中到高准确度区分11种癌症与对照（例如，胆管癌的曲线下面积=1.000）。在某些癌症中，表达与DNA甲基转移酶、错配修复基因、免疫检查点、肿瘤突变负担水平、微卫星不稳定性、新抗原计数和免疫浸润水平相关（<0.05）。该基因通过影响细胞因子-细胞因子受体相互作用等四种信号通路在多种癌症中发挥作用。高表达的癌症患者对包括ulixertinib在内的25种药物敏感。
与SARS-CoV-2相关的是一种可用于治疗和识别多种人类癌症的新型标志物。
